---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-010192"
form_type: "8-K"
ticker: "OGEN"
cik: "0001174940"
company_name: "ORAGENICS INC"
filed_at: "2024-03-18T23:59:59+00:00"
generated_at: "2026-06-04T14:34:12.153835+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Oragenics appoints Dr. James Kelly as CMO to lead Phase II concussion trial

## Summary
- Dr. Kelly will serve as CMO under an independent contractor agreement at $400/hour for 20 hours/month.
- He will oversee the Phase II trial of ONP-002, an intranasal NCE for mild traumatic brain injury.
- ONP-002 completed a 40-patient Phase I safety study; a 69 million annual concussion market cited.
- Dr. Kelly previously led the Marcus Institute for Brain Health and founded the NICoE at Walter Reed.
- Company is completing GMP drug manufacturing for the Phase II trial initiation.

## SEC filing metadata
- accession: 0001493152-24-010192
- form_type: 8-K
- ticker: OGEN
- cik: 0001174940
- company_name: ORAGENICS INC
- filed_at: 2024-03-18T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1174940/000149315224010192/0001493152-24-010192-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1174940/000149315224010192/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-010192
- JSON: https://secwatch.observer/filing/0001493152-24-010192.json
- Plain text: https://secwatch.observer/filing/0001493152-24-010192.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.